Bausch + Lomb Corporation (BLCO)
After hours:
| Previous close | 16.79 |
| Open | 16.95 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's range | 16.77 - 17.07 |
| 52-week range | 12.20 - 20.20 |
| Volume | |
| Avg. volume | 376,711 |
| Market cap | 5.895B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 22 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 29.83 |
- Business Wire
Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology
VAUGHAN, Ontario & HEIDELBERG, Germany, March 22, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in class ocular therapeutics, today announced that American Journal of Ophthalmology has published results from MOJAVE, the second pivotal Phase 3 trial for NOV03 (perfluorohexyloctane). NOV03 is being investigated to
- Simply Wall St.
Bausch + Lomb Full Year 2022 Earnings: EPS Misses Expectations
Bausch + Lomb ( NYSE:BLCO ) Full Year 2022 Results Key Financial Results Revenue: US$3.77b (flat on FY 2021). Net...
- Business Wire
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results
VAUGHAN, Ontario, February 22, 2023--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company", "we" or "our"), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2022 financial results.
